In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Sanofi gets rights to Lexicon's oral diabetes project sotagliflozin; approval troubles ensue, deal ends

Executive Summary

In its second diabetes deal announced in as many days, Sanofi licensed exclusive global rights to develop and sell Lexicon Pharmaceuticals Inc.'s oral Type I and Type II diabetes candidate sotagliflozin (LX4211).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register